[临床医学]2012ESC房颤管理指南更新.pdf

ICM Update on Consensus Statements ESC Internationales on Management of Atrial Fibrillation Congress Center European Heart Rhythm 2012 München Association Update of the ESC Guidelines on Medical Therapy 2012 John Camm St. George’s University of London United Kingdom ESC ICM - Internationales Congress Center München 2012 Update on Consensus Statements on Management of Atrial Fibrillation European Heart Rhythm Association Update of the ESC Guidelines on Medical Therapy 2012 John Camm Conflicts of Interest: Consultant/Advisor/Speaker Advisor / Speaker : Astra Zeneca, Gilead, Merck, Menarini, Sanofi Aventis, Servier, Xention, Bayer, Boehringer Ingleheim, Bristol Myers Squibb, Daiichi, Pfizer, Boston Scientific, Biotronik, Medtronic, St. Jude Medical, Actelion, GlaxoSmithKline, InfoBionic, Incarda, Johnson and Johnson, Mitsubishi, Novartis, Takeda Management of Atrial Fibrillation Focus of 2012 Update Anticoagulation risk stratification Use of novel oral anticoagulants (NOACs) Left atrial appendage occlusion/excision Pharmacological cardioversion (vernakalant) Oral antiarrhythmic therapy (dronedarone, and short term therapy) Left atrial catheter ablation European Heart Journal 2012 - doi:10.1093/eurheartj/ehs253 New /Modified Recommendations Topic A B C